Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

Issam Raad, Rabih Darouiche, Jose Vazquez, Arnold Lentnek, Ray Hachem, Hend Hanna, Beth Goldstein, Tim Henkel, Elyse Seltzer

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%-100.0%) that was significantly higher than that of those who received vancomycin (n = 34) (50.0%; 95% CI, 31.5%-68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.

Original languageEnglish (US)
Pages (from-to)374-380
Number of pages7
JournalClinical Infectious Diseases
Volume40
Issue number3
DOIs
StatePublished - Feb 1 2005

Fingerprint

Catheter-Related Infections
Safety
Coagulase
Gram-Positive Bacteria
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Staphylococcus
Staphylococcus aureus
Confidence Intervals
Glycopeptides
Therapeutics
Multicenter Studies
Length of Stay
Pharmacokinetics
Anti-Bacterial Agents
Costs and Cost Analysis
Mortality
dalbavancin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. / Raad, Issam; Darouiche, Rabih; Vazquez, Jose; Lentnek, Arnold; Hachem, Ray; Hanna, Hend; Goldstein, Beth; Henkel, Tim; Seltzer, Elyse.

In: Clinical Infectious Diseases, Vol. 40, No. 3, 01.02.2005, p. 374-380.

Research output: Contribution to journalArticle

Raad, I, Darouiche, R, Vazquez, J, Lentnek, A, Hachem, R, Hanna, H, Goldstein, B, Henkel, T & Seltzer, E 2005, 'Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens', Clinical Infectious Diseases, vol. 40, no. 3, pp. 374-380. https://doi.org/10.1086/427283
Raad, Issam ; Darouiche, Rabih ; Vazquez, Jose ; Lentnek, Arnold ; Hachem, Ray ; Hanna, Hend ; Goldstein, Beth ; Henkel, Tim ; Seltzer, Elyse. / Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. In: Clinical Infectious Diseases. 2005 ; Vol. 40, No. 3. pp. 374-380.
@article{f7906fa8426c4f72bcb31064af93a14c,
title = "Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens",
abstract = "Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0{\%}; 95{\%} confidence interval [CI], 73.2{\%}-100.0{\%}) that was significantly higher than that of those who received vancomycin (n = 34) (50.0{\%}; 95{\%} CI, 31.5{\%}-68.5{\%}). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.",
author = "Issam Raad and Rabih Darouiche and Jose Vazquez and Arnold Lentnek and Ray Hachem and Hend Hanna and Beth Goldstein and Tim Henkel and Elyse Seltzer",
year = "2005",
month = "2",
day = "1",
doi = "10.1086/427283",
language = "English (US)",
volume = "40",
pages = "374--380",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

AU - Raad, Issam

AU - Darouiche, Rabih

AU - Vazquez, Jose

AU - Lentnek, Arnold

AU - Hachem, Ray

AU - Hanna, Hend

AU - Goldstein, Beth

AU - Henkel, Tim

AU - Seltzer, Elyse

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%-100.0%) that was significantly higher than that of those who received vancomycin (n = 34) (50.0%; 95% CI, 31.5%-68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.

AB - Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%-100.0%) that was significantly higher than that of those who received vancomycin (n = 34) (50.0%; 95% CI, 31.5%-68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.

UR - http://www.scopus.com/inward/record.url?scp=13444257356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444257356&partnerID=8YFLogxK

U2 - 10.1086/427283

DO - 10.1086/427283

M3 - Article

C2 - 15668859

AN - SCOPUS:13444257356

VL - 40

SP - 374

EP - 380

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -